Zhejiang Hisun Pharmaceutical Co Ltd (600267):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zhejiang Hisun Pharmaceutical Co Ltd (600267) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7619
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zhejiang Hisun Pharmaceutical Co Ltd (Hisun) is a pharmaceutical company that manufactures and commercializes active pharmaceutical ingredients, antibiotics and anticancer drugs. The company offers active pharmaceutical ingredients and bulk drugs used in anti-neoplastics. It offers products in the areas of cardiovascular, anti-infection, anti-parasite, endocrine control, immunoinhibitors and anti-depression. Hisun offers active pharmaceutical ingredient such as acarbose, adenosine, bicalutamide, irbesartan, mevastatin, pitavastatin calcium, cladribine, cyclophosphamaide, rosuvastatin calcium, meropenem, imipenem, daptomycin, tobramycin and others. Hisun also offers contract manufacturing services. The company operates through its research and development facilities located in Shanghai and Beijing. Hisun is headquartered in Taizhou, Zhejiang, China.

Zhejiang Hisun Pharmaceutical Co Ltd (600267) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zhejiang Hisun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Infectious Disease Research Institute Enters into Agreement with Zhejiang Hisun Pharma 14
GeneriCo Enters into Distribution Agreement with Zhejiang Hisun Pharmaceutical 15
Celsion Enters into Agreement with Zhejiang Hisun Pharma 16
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 17
Zhejiang Hisun Pharma to Enter Co-Development Agreement with Ambrx 18
Catalent Pharma Enters Into An Agreement With Zhejiang Hisun Pharma To Develop Biosimilars 19
Celsion Expands Technology Development Agreement With Zhejiang Hisun Pharma 20
Celsion Enters Into Technology Development Agreement With Zhejiang Hisun Pharma For ThermoDox 21
Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 23
Zhejiang Hisun Pharma to Form Joint Venture With Beijing-Based Technology Company 24
Enzon Pharma Enters Into Co-Development Agreement With Zhejiang Hisun Pharma 25
Licensing Agreements 26
Zhejiang Hisun Pharma Enters into Licensing Agreement with Nascent Biotech 26
Zhejiang Hisun Pharma Enters into Licensing Agreement with Eli Lilly for Capreomycin 27
Enzon Pharma Enters Into Licensing Agreement With Zhejiang Hisun Pharma For PEG-SN38 28
Zhejiang Hisun Pharma Enters into Licensing Agreement with Fujifilm 29
Equity Offering 30
Zhejiang Hisun Pharma Plans to Raise up to USD143.8 Million in Private Placement of Shares 30
Zhejiang Hisun Pharma Receives Regulatory Approval for Private Placement of Shares 31
Debt Offering 32
Zhejiang Hisun Pharma Raises USD307.6 Million in Public Offering of Bonds 32
Zhejiang Hisun Pharma Prices Private Placement of Bonds for USD184 Million 33
Zhejiang Hisun Pharma Announces Private Placement Of Notes For Up To US$327 Million 34
Zhejiang Hisun Pharma Announces Public Offering Of Bonds 35
Acquisition 36
Zhejiang Hisun Pharma to Acquire 68% Stake in China Based Pharma Company for USD24.5 Million 36
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 37
Zhejiang Hisun Pharma to Acquire 15% Stake in Zhejiang-Based Pharma Company for USD12 Million 38
Zhejiang Hisun Pharma Acquires Respirics, Respiratory Drug Developer 39
Zhejiang Hisun Pharmaceutical Co Ltd – Key Competitors 40
Zhejiang Hisun Pharmaceutical Co Ltd – Key Employees 41
Zhejiang Hisun Pharmaceutical Co Ltd – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Joint Venture 42
Recent Developments 43
Other Significant Developments 43
Jul 20, 2017: HISUN’s first intelligent FDF production line is put operation on July 20th 2015 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zhejiang Hisun Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Zhejiang Hisun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Infectious Disease Research Institute Enters into Agreement with Zhejiang Hisun Pharma 14
GeneriCo Enters into Distribution Agreement with Zhejiang Hisun Pharmaceutical 15
Celsion Enters into Agreement with Zhejiang Hisun Pharma 16
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 17
Zhejiang Hisun Pharma to Enter Co-Development Agreement with Ambrx 18
Catalent Pharma Enters Into An Agreement With Zhejiang Hisun Pharma To Develop Biosimilars 19
Celsion Expands Technology Development Agreement With Zhejiang Hisun Pharma 20
Celsion Enters Into Technology Development Agreement With Zhejiang Hisun Pharma For ThermoDox 21
Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 23
Zhejiang Hisun Pharma to Form Joint Venture With Beijing-Based Technology Company 24
Enzon Pharma Enters Into Co-Development Agreement With Zhejiang Hisun Pharma 25
Zhejiang Hisun Pharma Enters into Licensing Agreement with Nascent Biotech 26
Zhejiang Hisun Pharma Enters into Licensing Agreement with Eli Lilly for Capreomycin 27
Enzon Pharma Enters Into Licensing Agreement With Zhejiang Hisun Pharma For PEG-SN38 28
Zhejiang Hisun Pharma Enters into Licensing Agreement with Fujifilm 29
Zhejiang Hisun Pharma Plans to Raise up to USD143.8 Million in Private Placement of Shares 30
Zhejiang Hisun Pharma Receives Regulatory Approval for Private Placement of Shares 31
Zhejiang Hisun Pharma Raises USD307.6 Million in Public Offering of Bonds 32
Zhejiang Hisun Pharma Prices Private Placement of Bonds for USD184 Million 33
Zhejiang Hisun Pharma Announces Private Placement Of Notes For Up To US$327 Million 34
Zhejiang Hisun Pharma Announces Public Offering Of Bonds 35
Zhejiang Hisun Pharma to Acquire 68% Stake in China Based Pharma Company for USD24.5 Million 36
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 37
Zhejiang Hisun Pharma to Acquire 15% Stake in Zhejiang-Based Pharma Company for USD12 Million 38
Zhejiang Hisun Pharma Acquires Respirics, Respiratory Drug Developer 39
Zhejiang Hisun Pharmaceutical Co Ltd, Key Competitors 40
Zhejiang Hisun Pharmaceutical Co Ltd, Key Employees 41
Zhejiang Hisun Pharmaceutical Co Ltd, Joint Venture 42

List of Figures
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zhejiang Hisun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Zhejiang Hisun Pharmaceutical Co Ltd (600267):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • American Municipal Power Inc:企業の発電所・SWOT分析2018
    American Municipal Power Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Fortinet Inc (FTNT):企業の財務・戦略的SWOT分析
    Fortinet Inc (FTNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Lund University-製薬・医療分野:企業M&A・提携分析
    Summary Lund University (LNU) is an educational service provider that offers master and bachelor programmes. It offers education and research in the areas of engineering, economics and management, science, law, social sciences, medicine, humanities, theology, fine art, music and others. The universi …
  • Linamar Corporation:企業の戦略・SWOT・財務情報
    Linamar Corporation - Strategy, SWOT and Corporate Finance Report Summary Linamar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Advanced Accelerator Applications SA (AAAP)-製薬・医療分野:企業M&A・提携分析
    Summary Advanced Accelerator Applications SA (AAA) is a healthcare products provider that offers molecular nuclear medicine and diagnostic and therapeutic products. The company’s lead product candidate comprises Lutathera, a lutetium-177 somatostatin analogue peptide that is used for the treatment o …
  • Bank Dhofar SAOG:企業の戦略・SWOT・財務分析
    Bank Dhofar SAOG - Strategy, SWOT and Corporate Finance Report Summary Bank Dhofar SAOG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Voltamp Energy SAOG (VOES):企業の財務・戦略的SWOT分析
    Voltamp Energy SAOG (VOES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Biosceptre International Ltd:企業の製品パイプライン分析2018
    Summary Biosceptre International Ltd (Biosceptre) is a biotechnology company that develops antibody technologies for applications in the diagnosis and treatment of cancer. The company develops imaging technologies to detect and monitor cancer. Its diagnostic products are used for the detection of va …
  • Pacific Coffee Company Ltd.:企業の戦略・SWOT・財務分析
    Pacific Coffee Company Ltd. - Strategy, SWOT and Corporate Finance Report Summary Pacific Coffee Company Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Medherant Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Medherant Ltd (Medherant) is a transdermal drug delivery patch company. The company develops and commercializes novel technologies for delivery of drugs through the skin using expertise in bioadhesives and polymer chemistry to treat pain, Alzheimer's disease, and for smoking cessation, hormo …
  • Max Delbruck Center for Molecular Medicine:製薬・医療:M&Aディール及び事業提携情報
    Summary Max Delbruck Center for Molecular Medicine (MDC) is a biomedical research center that offers translating discoveries from molecular research into applications. The company’s research area services offer for cancer research, cardiovascular and metabolic disease, diseases of the nervous system …
  • AFC Energy plc (AFC):電力:M&Aディール及び事業提携情報
    Summary AFC Energy plc (AFC Energy) is a developer of alkaline fuel cells. The company's projects include Power-Up and Alkammonia. Its power generation technology is used in the industrial markets and produces heat, water, and electricity. AFC Energy provides its electricity for industrial applicati …
  • NutriSystem Inc:企業の戦略的SWOT分析
    NutriSystem Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • CalciMedica Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CalciMedica Inc (CalciMedica) is a pharmaceutical company that develops small molecule drugs for the treatment of acute and chronic inflammatory and autoimmune disorders and organ transplant rejection. The company’s CM2489 is a compound developed to treat moderate plaque psoriasis. It also i …
  • Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析
    Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) …
  • Endotronix Inc:医療機器:M&Aディール及び事業提携情報
    Summary Endotronix Inc (Endotronix) is a medical technology company that offers digital health solutions. The company offers Cordella Heart Failure System with an implantable wireless pulmonary artery sensor for early detection of worsening heart failure. Endotronix’s solution includes an implanted …
  • North Eastern Electric Power Corporation Ltd:企業の戦略的SWOT分析
    North Eastern Electric Power Corporation Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Konica Minolta Inc (4902):医療機器:M&Aディール及び事業提携情報
    Summary Konica Minolta, Inc. (Konica Minolta) develops, manufactures and sells printing systems and solutions for production print professionals. The company’s product portfolio includes multi-functional peripherals (MFPs), printers, equipment for production print systems and graphic arts, equipment …
  • CMS Energy Corporation (CMS)-エネルギー分野:企業M&A・提携分析
    Summary CMS Energy Corporation (CMS Energy) is an energy utility which provides electricity, natural gas, and banking services. It generates, procures, transmits, distributes, and sells energy. The company produces power from coal, oil and gas, hydro, wind, and solar sources. CMS Energy purchases, t …
  • Owens‑Illinois, Inc.:企業の戦略・SWOT・財務情報
    Owens‑Illinois, Inc. - Strategy, SWOT and Corporate Finance Report Summary Owens‑Illinois, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆